FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation

V2, Crosslink

🧫

FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-ftld-tau

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation ## Background and Rationale This comprehensive clinical study addresses a critical need in frontotemporal lobar degeneration (FTLD) research by developing biomarkers to differentiate between tau-positive (FTLD-Tau) and TDP-43-positive (FTLD-TDP) pathological subtypes during life. Current clinical criteria cannot reliably distinguish these subtypes, which have different underlying molecular mechanisms, genetic risk factors, and potentially

METHODOLOGY NOTES

**Phase 1: Patient Recruitment and Clinical Characterization (Months 1-6)** Recruit 150 participants: 50 FTLD-Tau patients, 50 FTLD-TDP patients, and 50 age-matched healthy controls. Inclusion criteria include clinical diagnosis of FTLD based on consensus criteria, age 45-85 years, and availability of genetic testing results. Exclusion criteria include significant psychiatric comorbidities, recent immunosuppressive therapy, or contraindications to lumbar puncture or PET imaging. Conduct comprehensive neuropsychological assessment using Frontotemporal Lobar Degeneration-Clinical Dementia Rating (FTLD-CDR), Neuropsychiatric Inventory (NPI), and Frontal Behavioral Inventory (FBI). **Phase 2: Multimodal Biomarker Collection (Months 3-12)** Collect CSF via lumbar puncture for tau species analysis using ultrasensitive immunoassays (Simoa platform). Measure 4R-tau, 3R-tau, phospho-tau181, phospho-tau217, and TDP-43 levels. Perform [18F]MK-6240 tau-PET and [18F]AV-1451 imaging with quantita

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.897485Z'}
summary	# FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation ## Background and Rationale This comprehensive clinical study addresses a critical need in frontotemporal lobar degeneration (FTLD) research by
entities	{'genes': ['FTLD'], 'diseases': ["Alzheimer's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Validate FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
methodology_notes	Phase 1: Patient Recruitment and Clinical Characterization (Months 1-6) Recruit 150 participants: 50 FTLD-Tau patients, 50 FTLD-TDP patients, and 50 age-matched healthy controls. Inclusion criter
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.897490', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

680

Outgoing

548

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation

derives from (16)

supports (33)

💬 Discussion